

## **Key Indices Update**

Indices	Close	Change (%)
Nifty	24,853.15	0.997
Sensex	81,721.08	0.957
Midcap	56,687.75	0.647
Smallcap	17,643.35	0.807

### Trend Strength Indicator


Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
34	1731/ <mark>1132</mark>

### Key Data

Data	Current	Previous
Dow Jones	41,950.2	41,910.5
U.S. Dollar Index	98.88	99.76
Brent Crude (USD/BBL)	65.07	64.18
US 10Y Bond Yield (%)	4.52	4.53
India 10Y Bond Yield (%)	6.26	6.26

## Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	55398.55	0.837
NIFTYAUTO	23510.40	0.227
NIFTYENERG	35627.80	0.777
NIFTYFINSR	28456.05	1.127
NIFTYFMCG	56451.55	1.547
NIFTYIT	37402.25	0.957
NIFTYMEDIA	1678.55	0.277
NIFTYMETAL	9248.40	0.757
NIFTYPHARM	21438.40	ע0.39
NIFTYREALT	934.85	0.057



Market Radiance

: Read : Repeat

### **Top News**

- + ONGC and its JV partners, Hardy Exploration & Production (India) Inc. and Invenire Petrodyne Limited, have resumed production from the PY-3 Field in the Cauvery Basin. The field, which was originally brought online in 1997, had been shut down since July 2011.
- + RBI's Dividend Of ₹2.69 lakh crore for FY25 Is 27% more than FY24.

# Technical

Refer Page 03-04


- + Nifty witnessed some respite on the final trading day of the week, gaining nearly a percent amid mixed cues.
- + All key sectors, except pharma, contributed to the up move, with FMCG, financials, and IT emerging as the top gainers.
- Technically, the recovery after retesting the crucial short-term support level — the 20-day exponential moving average (20 DEMA) — has eased some pressure.
- + The outlook could improve further with renewed strength in the **banking and financial sectors** after their consolidation phase.
- + We maintain our view of adopting a "buy on dips" strategy, with a focus on selective stock picking, unless the Nifty decisively breaks below the 24,500 mark.
- + Stock of the day FEDERALBNK



Market Radiance

**Fundamental** 

Top News







# **Technical**

# Strong rebound after 20 DEMA retest. Stay focused on stock selection.

NIFTY	SI	S2	RI	R2	
24853.15 <b>7</b> 243.45 (0.99%)	24750	24650	24900	25100	



- Nifty witnessed some respite on the final trading day of the week, gaining nearly a percent amid mixed cues.
- All key sectors, except pharma, contributed to the up move, with FMCG, financials, and IT emerging as the top gainers.
- Technically, the recovery after retesting the crucial short-term support level

   the 20-day exponential moving average (20 DEMA) – has eased some pressure.
- + We maintain our view of adopting a "buy on dips" strategy, with a focus on selective stock picking, unless the Nifty decisively breaks below the 24,500 mark.

BANKNIFTY	S1	S2	R1	R2
55398.25 7 456.95 (0.83%)	55000	54600	55700	56100



- The banking index recovered from its intraday low after initial losses and closed marginally negative.
- + Mixed trend continued among the banking majors wherein Indusindbk witnessed gains while PNB and Axisbank remained top losers.
- The index reversed taking support of its 20
   EMA which shows resilience at lower levels but must hold the 54600-54400 zone to avoid further decline.
- On the upside, the index need decisive close above 55500-55700 for continuation of the uptrend.
- + Traders should keep a close watch on these levels and align their positions accordingly.



Market Radiance

# **Technica**l

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
FEDERALBNK	BUY	203.43	202-204	197	215

## Technical Chart : Weekly



	Name	Price	Price %
	MAHLIFE	340.50	26.567
db	FINPIPE	207.49	6.007
Midcap	STLTECH	72.05	5.277
	KNRCON	224.46	2.61
	DEEPAKFERT	1322.00	لا 2.90

well-defined rising channel on the long-term chart, reflecting a sustained uptrend.

Federal Bank continues to trade within a

- The stock has completed a bullish cup and handle formation, pointing toward a likely breakout after a four-month consolidation phase.
- Moreover, momentum indicators are also trending positively, reinforcing the bullish outlook.
- + Traders can consider to go long in the mentioned range.

Name	Price	Price %	
HINDCOPPER	237.50	4.887	Rang B
ICICIPRULI	643.50	3.837	ge B reak
MCX	6480.00	1.737	reak
ADANIPORTS	1393.50	1.617	/n ut,
DIXON	15025.00	<b>0.96</b>	

Name	Price	Price %	7
GMRAIRPORT	86.99	ע2.20	Top 5
CONCOR	722.00	لا2.16	F&O
NHPC	85.94	ו 1.78	
SUNPHARMA	1689.10	וא 1.72	Losers
JUBLFOOD	664.00	וב1.52	۲

Name	Price	Price %	
CUMMINSIND	2946.00	لا 1.06	Bearish
DIXON	15025.00	<b>0.96</b>	
JUBLFOOD	664.00	וב1.52	Charts
POLYCAB	5885.00	لا 1.06	rts
TORNTPHARM	3170.00	ו.31	

**Bullish Charts** 

Name	Price	Price %
ANGELONE	3065.00	5.207
BSE	2449.00	4.997
HINDCOPPER	237.50	4.887
MFSL	1473.70	4.227
VBL	488.35	4.007

Name	Price	Price %
ANGELONE	3065.00	5.207
BHEL	255.05	3.027
HDFCLIFE	780.65	3.287
ICICIPRULI	643.50	3.837
MFSL	1473.70	4.227



# Market Radiance Click : Read : Repeat

# **Research Team**

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com



# Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

#### Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/ are as under:

Statements on ownership and material conflicts of interest, compensation- Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Market Radiance

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results



